3,893 Shares in Quest Diagnostics Incorporated $DGX Acquired by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the 2nd quarter, Holdings Channel reports. The firm purchased 3,893 shares of the medical research company’s stock, valued at approximately $825,000.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Quest Diagnostics by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 14,392,082 shares of the medical research company’s stock worth $2,497,458,000 after purchasing an additional 140,450 shares in the last quarter. State Street Corp raised its stake in Quest Diagnostics by 3.0% in the fourth quarter. State Street Corp now owns 5,382,547 shares of the medical research company’s stock valued at $934,033,000 after buying an additional 158,617 shares in the last quarter. Boston Partners lifted its holdings in Quest Diagnostics by 32.8% during the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after buying an additional 997,033 shares during the last quarter. Morgan Stanley boosted its position in shares of Quest Diagnostics by 17.8% during the 4th quarter. Morgan Stanley now owns 2,693,568 shares of the medical research company’s stock worth $467,415,000 after acquiring an additional 406,658 shares in the last quarter. Finally, EdgePoint Investment Group Inc. boosted its position in shares of Quest Diagnostics by 35.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock worth $439,753,000 after acquiring an additional 582,797 shares in the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Trading Up 0.5%

NYSE:DGX opened at $236.71 on Wednesday. The company has a market capitalization of $26.13 billion, a PE ratio of 25.13, a P/E/G ratio of 2.16 and a beta of 0.56. Quest Diagnostics Incorporated has a 52-week low of $171.18 and a 52-week high of $240.13. The stock’s 50 day moving average price is $217.00 and its 200 day moving average price is $204.06. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, research analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be given a $0.86 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 annualized dividend and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio is 36.52%.

Analyst Ratings Changes

DGX has been the topic of several research analyst reports. Mizuho raised their target price on Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Jefferies Financial Group reissued a “buy” rating and set a $245.00 price objective on shares of Quest Diagnostics in a report on Thursday, July 23rd. Evercore set a $225.00 price objective on shares of Quest Diagnostics in a research report on Tuesday, April 21st. JPMorgan Chase & Co. upped their target price on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings raised shares of Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $235.31.

Insider Buying and Selling

In other news, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the sale, the senior vice president directly owned 13,510 shares of the company’s stock, valued at approximately $2,702,000. This represents a 37.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at $25,708,601.22. This trade represents a 7.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,747 shares of company stock worth $3,947,088 in the last 90 days. Company insiders own 0.88% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.